Academic/Biomedical Research
News & Jobs

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

Get Our Industry eNewsletter FREE

email:

Hemispherx Biopharma (HEB) Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)

3/26/2012 10:11:36 AM

PHILADELPHIA, March 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE Amex:HEB) announced the publication of a peer-reviewed article in the Journal of Interferon and Cytokine Research (Volume 32, pages 95-102) providing an analysis of the incidence and clinical impact of neutralizing antibodies (NABs) formed during treatment with recombinant interferons (a-2a, a-2b, ß-1a and ß-1b) compared to natural interferons (a-n1 or a-n3), such as Alferon N Injection®. The recombinant interferons induced seroconversion with the generation of NABs in 17.2% of patients studied. Seroconversion is the development of detectable specific antibodies. Antibodies can sometimes attack a pharmaceutical administered to the body eventually inhibiting the effect of the medication.

Read at GlobeNewswire

• GlobeNewswire

• Hemispherx Biopharma Inc.

• Clinical - Research